News
The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...
The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...
1d
Stocktwits on MSNMoleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ SetupRetail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...
1d
Clinical Trials Arena on MSNEMA approves Moleculin’s application for Phase IIb/III AML trialThe European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...
Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...
5d
MedPage Today on MSNDrug Used by Trump Has Suicide Risk; FDA's 'Aggressive' AI Rollout; 1K Measles CasesThoughts of suicide was confirmed as a side effect of finasteride (Propecia, Proscar), the European Medicines Agency (EMA) ...
The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...
Few areas of healthcare are as sensitive as cancer treatment. Each year, around 44,000 cancer tumours are diagnosed here.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results